A generic version of the anti-cancer drug eribulin, which is currently marketed under the brand name Halaven by Eisai Pharmaceuticals, is now available in India.
The generic eribulin will be 40% less than Halavan, said Emcure Pharmaceuticals, which launched the cancer treatment knock-off.
Eribulin, originally isolated halichondrin B from the natural Japanese marine sponge Halichondria okadai, was approved by the US FDA on November 15, 2010 for the treatment of metastatic breast cancer.
Considered less toxic, eribulin is currently used as second-line treatment for relapsing triple-negative breast cancer. Triple-negative breast cancer is tough to treat as the patients with this sub-type are tested negative for all the three receptor proteins — oestrogen, progesterone as well as HER2.
Eisai won the second approval from the US FDA for eribulin in January 2016 or the treatment of liposarcoma in patients who had undergone anthracycline-based chemotherapy.
Presently, eribulin is being investigated for use in various cancers such as non-small cell lung cancer, prostate cancer and sarcoma.